Medical isotope developer IsoRay has signed a manufacturing contract with Pacific Northwest National Laboratories (PNNL) and the U.S. Department of Energy (DOE) to collaborate in the manufacture of cesium-131 brachytherapy seeds, according to the Richland, WA-based firm.
The Cs131 seed is the only brachytherapy seed approved by the Food and Drug Administration that meets the American Association of Physicists in Medicine (AAPM) guidelines for the clinical treatment of prostate cancer and other malignant disease, IsoRay said. The firm said that during the contract period, which expires September 30, 2005, it expects to finalize plans for the construction of its own manufacturing facility.
By AuntMinnie.com staff writersMay 11, 2004
Copyright © 2004AuntMinnie.com
